BC 002 - Dragonboat Biopharmaceutical
Alternative Names: BC002 - Dragonboat BiopharmaceuticalLatest Information Update: 19 Feb 2022
At a glance
- Originator Dragonboat Biopharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 07 Feb 2022 Phase-I clinical trials in Solid tumours in China (Parenteral) before February 2022 (Dragonboat Biopharmaceutical, February 2022)
- 06 Feb 2022 Preclinical trials in Solid tumours in China (Parenteral) before February 2022 (Dragonboat Biopharmaceutical, February 2022)